Dr Reddy's gets four observations from USFDA for Andhra plant

Published On 2019-01-19 04:00 GMT   |   Update On 2021-08-17 06:11 GMT


"The audit of our formulations Srikakulum Plant (SEZ) Unit I, Andhra Pradesh by the US Food and Drug Administration (USFDA), has been completed today. We have been issued a Form 483 with 4 observations, which we are addressing," Dr Reddy's said in a regulatory filing.


Hyderabad: Dr Reddy's Laboratrories recently said the US health regulator has issued four observations after inspecting its formulations unit in Andhra Pradesh.


"The audit of our formulations Srikakulum Plant (SEZ) Unit I, Andhra Pradesh by the US Food and Drug Administration (USFDA), has been completed today. We have been issued a Form 483 with 4 observations, which we are addressing," the Hyderabad-based company said in a regulatory filing.


Read Also: Dr Reddy's launches Aspirin and Dipyridamole capsules in US market


As per the USFDA, Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that in its judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.


It notifies the company's management of objectionable conditions.





Dr Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad, Telangana, India. The company was founded by Anji Reddy, who previously worked in the mentor

institute Indian Drugs and Pharmaceuticals Limited, of Hyderabad, India.

Tags:    
Article Source : With input

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News